Value Sense
ABBV
AbbVie Inc. (ABBV)
Last Price$213.6(1.4%)
Market Cap$375.8B
P/BV LTM
51.3x
5Y avg
16.7x
Drug Manufacturers - General industry median
5.4x
Stock quality & Intrinsic value
6/10
0.4% undervalued
ABBV
is 41.6% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

AbbVie Inc. P/BV LTM

Annual
Quarterly
Daily
Crunching data... Almost there!
Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
P/BV LTM
3.5x
23.5x
22.7x
19.8x
15.4x
23.1x
(46.7x)
(16.0x)
12.2x
17.8x
17.8x
22.6x
51.3x
ABBV
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for ABBV and see if it's the right time to invest.
Dive in

AbbVie Inc. (ABBV) P/BV LTM comparison analysis

General

LTM P/BV LTM

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

AbbVie Inc. logo
AbbVie Inc.ABBV
111.7x
3.7%
(11.4%)
7.6%
Median Peer Set
5.6x
9.8%
11.0%
14.4%
Eli Lilly and Company logo
Eli Lilly and CompanyLLY
52.1x
32.0%
102.4%
23.5%
Amgen Inc. logo
Amgen Inc.AMGN
29.4x
18.6%
(39.8%)
12.2%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
16.5x
24.9%
142.8%
34.8%
Gilead Sciences, Inc. logo
Gilead Sciences, Inc.GILD
7.4x
6.0%
(91.6%)
1.7%
AstraZeneca PLC logo
AstraZeneca PLCAZN
5.7x
18.0%
18.9%
13.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
5.6x
4.3%
(57.9%)
15.8%
Merck & Co., Inc. logo
Merck & Co., Inc.MRK
5.2x
6.7%
4,714.3%
26.7%
Novartis AG logo
Novartis AGNVS
5.1x
10.8%
(16.5%)
23.1%
Sanofi logo
SanofiSNY
1.7x
(3.8%)
3.1%
12.6%
Pfizer Inc. logo
Pfizer Inc.PFE
1.7x
8.8%
273.7%
12.6%

ABBV key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Revenue
% growth
14,214.2
0.0%
15,638.0
10.0%
17,444.0
11.5%
18,380.0
5.4%
18,790.0
2.2%
19,960.0
6.2%
22,859.0
14.5%
25,638.0
12.2%
28,216.0
10.1%
32,753.0
16.1%
33,266.0
1.6%
45,804.0
37.7%
56,197.0
22.7%
58,054.0
3.3%
54,318.0
(6.4%)
56,334.0
3.7%
Cost of Goods Sold (COGS)4,056.44,293.04,639.44,508.04,581.04,426.04,500.05,833.07,040.07,718.07,439.015,387.017,446.017,414.020,415.016,904.0
Gross Profit
% margin
10,157.8
71.5%
11,345.0
72.5%
12,804.6
73.4%
13,872.0
75.5%
14,209.0
75.6%
15,534.0
77.8%
18,359.0
80.3%
19,805.0
77.2%
21,176.0
75.0%
25,035.0
76.4%
25,827.0
77.6%
30,417.0
66.4%
38,751.0
69.0%
40,640.0
70.0%
33,903.0
62.4%
39,430.0
70.0%
Operating Expenses5,056.06,315.08,511.37,767.08,207.011,771.010,672.010,221.011,257.018,228.012,459.017,856.019,865.021,826.021,146.030,293.0
Research & Development Expenses (R&D)1,707.42,495.02,617.52,778.02,855.03,297.04,285.04,366.04,982.010,329.06,407.06,557.07,084.06,510.08,453.012,791.0
Selling, General & Administrative Expenses (SG&A)3,348.63,820.05,893.84,989.05,352.07,724.06,387.05,855.06,275.07,399.06,942.011,299.012,349.015,260.012,872.014,752.0
Operating Income
% margin
4,931.8
34.7%
4,717.0
30.2%
3,620.7
20.8%
6,622.0
36.0%
5,664.0
30.1%
3,411.0
17.1%
7,537.0
33.0%
9,340.0
36.4%
9,545.0
33.8%
6,383.0
19.5%
12,983.0
39.0%
11,363.0
24.8%
17,924.0
31.9%
18,117.0
31.2%
12,757.0
23.5%
9,137.0
16.2%
Interest Income0.028.020.020.021.038.033.082.0146.0204.0275.0174.039.0186.0540.0648.0
Interest Expense0.00.00.0104.0299.0429.0719.01,047.01,150.01,348.01,784.02,454.02,423.02,230.02,224.02,808.0
Pre-tax Income5,950.34,836.03,668.55,725.05,332.02,369.06,645.07,884.07,727.05,197.08,426.03,398.012,989.013,477.06,250.03,716.0
Income Tax
% effective tax rate
1,313.8
22.1%
658.0
13.6%
235.4
6.4%
450.0
7.9%
1,204.0
22.6%
595.0
25.1%
1,501.0
22.6%
1,931.0
24.5%
2,418.0
31.3%
490.0
9.4%
544.0
6.5%
1,224.0
36.0%
1,440.0
11.1%
1,632.0
12.1%
1,377.0
22.0%
(570.0)
(15.3%)
Net Income
% margin
4,636.5
32.6%
4,178.0
26.7%
3,433.1
19.7%
5,275.0
28.7%
4,128.0
22.0%
1,774.0
8.9%
5,144.0
22.5%
5,953.0
23.2%
5,309.0
18.8%
5,687.0
17.4%
7,882.0
23.7%
4,616.0
10.1%
11,542.0
20.5%
11,836.0
20.4%
4,863.0
9.0%
4,278.0
7.6%
EPS2.872.592.123.352.581.113.153.653.313.695.302.736.486.652.732.42
Diluted EPS2.852.572.113.352.561.103.133.633.303.685.282.726.456.632.722.41
EBITDA
% margin
6,647.8
46.8%
6,020.0
38.5%
4,940.7
28.3%
6,979.0
38.0%
6,914.0
36.8%
6,286.0
31.5%
9,692.0
42.4%
10,812.0
42.2%
11,774.0
41.7%
13,688.0
41.8%
16,264.0
48.9%
21,148.0
46.2%
28,280.0
50.3%
31,424.0
54.1%
17,308.0
31.9%
14,910.0
26.5%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is AbbVie Inc.'s P/BV LTM?

As of today, Microsoft Corp's last 12-month P/BV LTM is 51.3x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/BV LTM for AbbVie Inc. have been 24.4x over the past three years, and 17.6x over the past five years.

2) Is AbbVie Inc.'s P/BV LTM Good?

As of today, AbbVie Inc.'s P/BV LTM is 51.3x, which is higher than industry median of 5.4x. It indicates that AbbVie Inc.'s P/BV LTM is Bad.

3) How does AbbVie Inc.'s P/BV LTM compare to its peers?

As of today, AbbVie Inc.'s P/BV LTM is 51.3x, which is higher than peer median of 5.6x. The list of peers includes LLY, AMGN, NVO, GILD, AZN, JNJ, MRK, NVS, SNY, PFE.